Efficacy of PD-1 inhibitor can be influenced by tumor microenvironment (TME), while immunosuppressive TME correlates with poor prognosis and resistants to chemotherapy (12–14) and PD-1 inhibitor (15, 16). Here, PDCD1 is linked to neoplasm.